NovaBridge Biosciences: Form 20-F for the period ended Dec 31, 2021
Filed with the SEC on Apr 29, 2022 and accepted by EDGAR at Apr 29, 2022, 16:06 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2021-01-01 to 2021-12-31 | $13.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2021-01-01 to 2021-12-31 | $7.3m | us-gaap:CostOfRevenue |
| Research and development | 12 months2021-01-01 to 2021-12-31 | $190.3m | us-gaap:ResearchAndDevelopmentExpense |
| Interest expense | 12 months2021-01-01 to 2021-12-31 | $0 | us-gaap:InterestExpense |
| Income tax | 12 months2021-01-01 to 2021-12-31 | −$495.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2021-01-01 to 2021-12-31 | −$365.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2021-01-01 to 2021-12-31 | −$2.09 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2021-01-01 to 2021-12-31 | −$2.09 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2021-01-01 to 2021-12-31 | 174,707,055 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2021-01-01 to 2021-12-31 | −$152.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2021-01-01 to 2021-12-31 | $4.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-12-31 | $552.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-12-31 | $750.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-12-31 | $878.9m | us-gaap:Assets |
| Current liabilities | At period end2021-12-31 | $97.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-12-31 | $163.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-12-31 | $715.5m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2021-12-31 | 183,826,753 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001193125-22-133550. Last ingested by Listed: Nov 6, 2026, 02:19 ET. Listed shows no prices and gives no investment advice.